Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Advocacy

Displaying 53 papers

Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships

Publication: Brooks AD, Wells WA, McLean TD, et. al. Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships. 2010. Innovation Strategy Today 2010 Jan. 3:1-5.

1/2010

Tags: Advocacy, Policy, Regimen Change, TB Market

Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development

Publication: Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009 Dec;30(4):755-68, ix. doi: 10.1016/j.ccm.2009.08.011.

12/2009

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, MDR-TB, TB-HIV

Assessment of global capacity to conduct tuberculosis drug development trials- do we have what it takes

Publication: van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 2009 Nov;13(11):1367-72. http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000011/a

11/2009

Tags: Advocacy, Clinical Development, Policy

Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on

Publication: Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3726-33. doi: 10.1128/AAC.00112-09

6/2009

Tags: Advocacy, Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Acid Resistance in Mycobacterium tuberculosis

Publication: Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.

5/2009

Tags: Advocacy, Drug Discovery, Drug Targets, M.tb. Biology

Timing of Default From Tuberculosis Treatment: A Systematic Review

Publication: Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health. 2008 May;13(5):703-12. doi: 10.1111/j.1365-3156.2008.02042.x.

5/2008

Tags: Advocacy, Policy, Regimen Change, TB Market

The ethics of non-inferiority trials

Publication: Nunn AJ, Meredith SK, Spigelman MK, Ginsberg AM, Gillespie SH. The ethics of non-inferiority trials. Lancet. 2008 Mar 15;371(9616):895; author reply 896-7. doi: 10.1016/S0140-6736(08)60404-3.

3/2008

Tags: Advocacy, Clinical Development, Clinical Trial Results, Editorials, Policy, Trial Design

Challenges associated with current and future TB treatment

Publication: Laurenzi M, Ginsberg AM, Spigelman M. Challenges associated with current and future TB treatment. Infect Disord Drug Targets. 2007 Jun;7(2):105-19. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00004?token=004e1567d370e7e442f206

Author(s): Laurenzi, M., A. Ginsberg, and M. Spigelman

6/2007

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, Trial Design

Planning to improve global health: the next decade of tuberculosis control

Publication: Dermot Maher, Chris Dye, Katherine Floyd, et. al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ. 2007 May; 85(5): 341–347. doi: 10.2471/06.037820

5/2007

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB-HIV

Tuberculosis drug development pipeline: progress and hope

Publication: Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet. 2006 Mar 18;367(9514):945-7. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)68388-8/abstract. Accessed March 7, 2016

3/2006

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline

Opportunities for overcoming tuberculosis: new treatment regimens

Publication: Freire MC. Opportunities for overcoming tuberculosis: new treatment regimens. World Hosp Health Serv. 2006;42(1):34-7. http://www.ncbi.nlm.nih.gov/pubmed/16669375. Accessed March 7, 2016

1/2006

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, Policy, Trial Design

Mycobacterium tuberculosis: new tricks for an old bug

Publication: Spigelman M, Ma Z. Mycobacterium tuberculosis: new tricks for an old bug. Expert Rev Anti Infect Ther. 2004 Aug;2(4):467-9.https://www.researchgate.net/publication/8234528_Mycobacterium_tuberculosis_New_tricks_for_an_old_bug. Accessed March 7, 2016

8/2004

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials, Global Pipeline, Pharmacokinetics

Joining forces to develop weapons against TB: together we must.

Publication: Freire M, Roscigno G. Joining forces to develop weapons against TB: together we must. Bull World Health Organ. 2002;80(6):429. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567524/pdf/12131997.pdf. Accessed March 7, 2016

1/2002

Tags: Advocacy, Editorials, MDR-TB, Moxifloxacin, Pretomanid/PA-824, TB-HIV

Pages